/
We are a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer s disease ( AD ), for which there are limited or no treatment options. We focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation.
The business is unprofitable at the operating level (-221.72% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$21M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$11M
Net Income (TTM)
-$25M
▼ -39.8% YoY
Op. Margin
-252.66%
ROIC
-45.92%
▲ +9.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$30M
▼ -165.7% YoY
Op. Cash Flow (TTM)
-$30M
▼ -162.8% YoY
Net Debt
-$54M
Net Cash Position
Cash & Equiv.
$54M
Continue Research